guest ::
| Home > Publications database > Tumor-specific regulatory T cells from the bone marrow orchestrate antitumor immunity in breast cancer. > print |
| Home > Publications database > Tumor-specific regulatory T cells from the bone marrow orchestrate antitumor immunity in breast cancer. > print |
| 001 | 147406 | ||
| 005 | 20240229112650.0 | ||
| 024 | 7 | _ | |a 10.1158/2326-6066.CIR-18-0763 |2 doi |
| 024 | 7 | _ | |a pmid:31672785 |2 pmid |
| 024 | 7 | _ | |a 2326-6066 |2 ISSN |
| 024 | 7 | _ | |a 2326-6074 |2 ISSN |
| 024 | 7 | _ | |a altmetric:89771200 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-02523 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ge, Yingzi |0 P:(DE-He78)a680dbb93cb7ae62c0456b04cb13567b |b 0 |e First author |
| 245 | _ | _ | |a Tumor-specific regulatory T cells from the bone marrow orchestrate antitumor immunity in breast cancer. |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2019 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1576238930_13910 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 7(12):1998-2012 |
| 520 | _ | _ | |a Endogenous antitumor effector T cell responses and immune suppressive regulatory T cells (Tregs) critically influence the prognosis of cancer patients, yet many of the mechanisms of how this occurs remain unresolved. Based on an analysis of the function, antigen-specificity and distribution of tumor antigen-reactive T cells and Tregs in breast cancer patients and transgenic mouse tumor models we showed that tumor-specific Tregs were selectively activated in the bone marrow (BM) and egressed into the peripheral blood (PB). The BM was constantly depleted of tumor-specific Tregs and was instead a site of increased induction and activity of tumor-reactive effector/memory T cells. Treg egress from the BM was associated with activation-induced expression of peripheral homing receptors such as CCR2. Since breast cancer tissues express the CCR2 ligand CCL2, the activation and egress of tumor antigen-specific Tregs in the BM resulted in the accumulation of Tregs in breast tumor tissue. Such immune-compartmentalization and redistribution of T cell subpopulations between the BM and peripheral tissues was achieved by vaccination with adenoviral vector encoded TRP-2 tumor antigen in a RET transgenic mouse model of spontaneous malignant melanoma. Thus, the BM simultaneously represented a source of tumor-infiltrating Tregs and a site for the induction of endogenous tumor-specific effector T cell responses, suggesting that both antitumor immunity and local immune suppression are orchestrated in the BM. |
| 536 | _ | _ | |a 314 - Tumor immunology (POF3-314) |0 G:(DE-HGF)POF3-314 |c POF3-314 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Böhm, Hans-Henning |0 P:(DE-He78)bdea8d359afbb726cce05b82d7b01669 |b 1 |e First author |
| 700 | 1 | _ | |a Rathinasamy, Anchana |0 P:(DE-He78)a4d37cf08789986f17ff6ceb579e396e |b 2 |e First author |
| 700 | 1 | _ | |a Xydia, Maria |0 P:(DE-He78)d3f0a48c15b355dfeae29fd5137d8bcb |b 3 |
| 700 | 1 | _ | |a Hu, Xiaoying |0 P:(DE-He78)9f73dd6f3a8b9ba22a653f5d0257bd6f |b 4 |
| 700 | 1 | _ | |a Pincha, Mudita |0 P:(DE-He78)74f34d9a816946005cede7ae8df5b260 |b 5 |
| 700 | 1 | _ | |a Umansky, Ludmila |0 P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45 |b 6 |
| 700 | 1 | _ | |a Breyer, Christopher |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Hillier, Michael |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Bonertz, Andreas |0 0000-0002-6846-9265 |b 9 |
| 700 | 1 | _ | |a Sevko, Alexandra |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Domschke, Christoph |b 11 |
| 700 | 1 | _ | |a Schuetz, Florian |b 12 |
| 700 | 1 | _ | |a Frebel, Helge |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Dettling, Steffen |b 14 |
| 700 | 1 | _ | |a Herold-Mende, Christel C |b 15 |
| 700 | 1 | _ | |a Reissfelder, Christoph |b 16 |
| 700 | 1 | _ | |a Weitz, Juergen |b 17 |
| 700 | 1 | _ | |a Umansky, Viktor |0 P:(DE-He78)38be34240daf8b47325afc7910e77f7b |b 18 |
| 700 | 1 | _ | |a Beckhove, Philipp |0 P:(DE-He78)1732377f6242a18280bc6aaa196988d1 |b 19 |e Last author |
| 773 | _ | _ | |a 10.1158/2326-6066.CIR-18-0763 |g p. canimm.0763.2018 - |0 PERI:(DE-600)2732517-9 |n 12 |p 1998-2012 |t Cancer immunology research |v 7 |y 2019 |x 2326-6074 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:147406 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)a680dbb93cb7ae62c0456b04cb13567b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)bdea8d359afbb726cce05b82d7b01669 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)a4d37cf08789986f17ff6ceb579e396e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)d3f0a48c15b355dfeae29fd5137d8bcb |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)9f73dd6f3a8b9ba22a653f5d0257bd6f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)74f34d9a816946005cede7ae8df5b260 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 0000-0002-6846-9265 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)38be34240daf8b47325afc7910e77f7b |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-314 |2 G:(DE-HGF)POF3-300 |v Tumor immunology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER IMMUNOL RES : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCER IMMUNOL RES : 2017 |
| 920 | 1 | _ | |0 I:(DE-He78)D015-20160331 |k D015 |l Translationale Immunologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A370-20160331 |k A370 |l KKE Dermatoonkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D015-20160331 |
| 980 | _ | _ | |a I:(DE-He78)A370-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|